Adalvo develops pharmaceutical dossiers, owns intellectual property, and builds regulatory strategies behind high-quality generic medicines marketed by leading global pharmaceutical companies. Today, more than 1.3 million patients have been treated with Adalvo medicines, while over 60 new development projects are planned for launch over the next five years. Adalvo combines a portfolio, IP strategy, and a global partner network to unlock opportunities earlier and faster.

What makes Adalvo differentiated is its technology and indication agnostic platform, first-to-file and first-to-market capabilities, double-sourced non-infringing resilient supply chains, and an organizational mindset of being fast and reliable.

Company’s declared purpose is to make a difference for patients around the world through a collaboration network and a commitment to deliver the quality differentiated products and services to its partners.